What Fueled The Previous Growth In The Leukemia Therapeutics Market?
The leukemia therapeutics market has seen considerable growth due to a variety of factors.
• In recent times, the leukemia therapeutics market has seen significant expansion. The market size is poised to grow from $17.57 billion in 2024 to $18.85 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%.
Factors that contributed to the growth in the historic period include a rise in the elderly population, advancements in diagnostics that facilitate early detection of leukemia, a rising occurrence rate of leukemia, an upsurge in research and development funding, and the broadening scope of personalized medicine practices.
What Is The Expected Growth In The Leukemia Therapeutics Market Size?
The leukemia therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for leukemia therapeutics is anticipated to experience robust growth in the upcoming years, predicted to reach $25.91 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.3%.
Numerous factors driving this growth in the forecasted period include the emergence of innovative immunotherapies for treating leukemia, an expanded focus on precision medicine for the disease, broadening the indications for existing leukemia treatments, a rise in the use of gene therapies, and advancements in supportive care for leukemia patients. Key trends during this forecast period encompass the incorporation of biomarker-driven strategies, the ascendance of combination therapies for improved efficacy, focus on monitoring minimal residual disease, an uptick in the employment of car-t cell therapies, and the investigation of targeted therapies tailored to specific leukemia subtypes.
What Are the Critical Driver Fuelling the Leukemia Therapeutics Market's Growth?
The escalation in leukemia cases is fueling the expansion of the leukemia therapeutics market. Leukemia, a blood cancer that originates in the bone marrow and results in unruly blood cell proliferation, is becoming more common. The growing global access to medical treatments for leukemia and the increasing availability of diverse treatment options is leading to a higher demand for leukemia therapeutic solutions. For instance, a January 2023 report from the U.S. based American Cancer Society predicts roughly 59,610 new leukemia cases of varying types and around 23,710 deaths from leukemia in the same year. Furthermore, an estimated 20,380 fresh cases of acute myeloid leukemia (AML) and nearly 11,310 AML-related deaths are predicted for the same year. Thus, the rising incidence of leukemia is clearly promoting the expansion of the leukemia therapeutics market.
How Is the Leukemia Therapeutics Market segmented?
The leukemia therapeutics market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Immunotherapy, Targeted Therapy, Other Treatments
2) By Type Of Leukemia: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Type Of Leukemia
3) By Molecule Type: Small Molecules, Biologics
4) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Chemotherapy: Alkylating Agents, Antimetabolites, Plant Alkaloids, Corticosteroids
2) By Immunotherapy: Monoclonal Antibodies, CAR T-Cell Therapy, Immune Checkpoint Inhibitors, Vaccines
3) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), BCL-2 Inhibitors, IDH Inhibitors, Other Targeted Agents
4) By Other Treatments: Radiation Therapy, Stem Cell Transplantation, Supportive Care Treatments
Pre-Book The Leukemia Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing the Leukemia Therapeutics Market?
Leading firms in the leukemia therapeutics market are using strategic partnerships to aid in the launch and commercialization of their first advanced cancer treatments in the United States. These alliances are a mechanism through which companies utilize each other's capabilities and assets to gain shared benefits and accomplish mutual success. For example, in February 2023, Xspray Pharma AB, a biotech company based in Sweden, formed a partnership with EVERSANA, an American firm offering commercial services to the life sciences sector. The collaboration is meant to assist in the U.S. debut and commercialization of the company's inaugural groundbreaking cancer treatment, Dasynoc, designed for managing chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Xspray Pharma will maintain financial and strategic oversight, while granting EVERSANA exclusive commercial rights to support the launch of Dasynoc, planned for the latter half of 2023.
Who Are the Key Players in the Leukemia Therapeutics Market?
Major companies operating in the leukemia therapeutics market include:
• Novartis International AG
• AbbVie Inc.
• Bristol Myers Squibb Company
• F. Hoffmann-La Roche AG
• Sanofi S. A.
• Agios Pharmaceuticals
• Amgen Inc.
• Argenx SE
• Astellas Pharma Inc.
• BioLineRx Ltd.
• Cellerant Therapeutics Inc.
• Daiichi Sankyo Company Limited
• Forma Therapeutics Inc.
• Gilead Sciences Inc.
• Incyte Corporation
• Jazz Pharmaceuticals plc
• Johnson & Johnson
• Mirati Therapeutics Inc.
• Molecular Templates Inc.
• Ono Pharmaceutical Co. Ltd.
• Pfizer Inc.
• Seattle Genetics Inc.
• Stemline Therapeutics Inc.
• Sunesis Pharmaceuticals Inc.
• Takeda Pharmaceutical Company Limited
• TG Therapeutics Inc.
• Allogene Therapeutics Inc.
• Blueprint Medicines Corporation
• Karyopharm Therapeutics Inc.
• Verastem Oncology Inc.
What Is The Most Dominant Region In The Leukemia Therapeutics Market?
North America was the largest region in the leukemia therapeutics market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukemia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
